European Society for Medical Oncology Congress
Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer
The combination of nivolumab and ipilimumab after nephrectomy failed to extend DFS among patients with localized renal cell carcinoma at high risk for relapse, results of the phase 3 CheckMate 914 trial showed.
ESMO presentations highlight advances in kidney cancer, melanoma, lung cancer
This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.
Long-course ADT plus radiotherapy provides survival benefit after prostatectomy
Long-course androgen depravation therapy extended metastasis-free survival compared with short-course ADT when added to radiotherapy after radical prostatectomy, results of the randomized phase 3 RADICALS-HD trial showed.
Sotorasib delays progression of advanced KRAS-mutant non-small cell lung cancer
Sotorasib significantly extended PFS compared with standard-of-care docetaxel as second-line therapy for patients with KRASG12C-mutated non-small cell lung cancer, data from the randomized phase 3 CodeBreak 200 trial showed.
Pembrolizumab plus chemoradiotherapy shows favorable EFS trend in head/neck cancer
The addition of pembrolizumab to chemoradiotherapy demonstrated a trend toward longer EFS among patients with locally advanced head and neck squamous cell carcinoma, according to data presented at ESMO Congress.
Short-course neoadjuvant immunotherapy confers high response rates in colon cancer subset
Two cycles of neoadjuvant nivolumab plus low-dose ipilimumab induced durable pathologic responses among patients with mismatch repair-deficient colon cancer, according to study results presented at ESMO Congress.
Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup
The addition of abemaciclib to a nonsteroidal aromatase inhibitor prolonged median OS by more than a year among patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to data presented at ESMO Congress.
Timing of pembrolizumab makes a difference in resectable melanoma
Neoadjuvant pembrolizumab extended event-free survival compared with adjuvant-only administration of the anti-PD-1 therapy among patients with resectable melanoma, according to phase 2 study results presented at ESMO Congress.
Cell therapy doubles survival, response rates in advanced melanoma
A single infusion of tumor-infiltrating lymphocytes more than doubled PFS, OS and complete response rates compared with ipilimumab among patients with advanced, unresectable melanoma, study results presented at ESMO Congress showed.
Nirogacestat may become standard of care for patients with rare desmoid tumors
Nirogacestat significantly improved PFS compared with placebo among patients with progressing desmoid tumors, according to phase 3 study results presented at ESMO Congress.